Welcome to our dedicated page for Proqr Therapeuti SEC filings (Ticker: PRQR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ProQR Therapeutics N.V. (Nasdaq: PRQR) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a foreign private issuer. ProQR files annual reports on Form 20-F and periodic current reports on Form 6-K, which include press releases, unaudited financial statements, and materials from analyst and investor events. These filings document the evolution of ProQR’s Axiomer RNA editing platform, its clinical and preclinical pipeline, and its financial position over time.
Recent Form 6-K filings referenced by ProQR furnish unaudited financial statements for quarterly periods and press releases such as “ProQR Announces Third Quarter 2025 Operating and Financial Results” and “ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook.” Other 6-Ks include materials from a virtual analyst and investor event focused on the AX-0810 Phase 1 trial design and biomarker strategy, and announcements related to the submission and authorization of a Clinical Trial Application for AX-0810 targeting NTCP.
For investors analyzing PRQR, these filings provide detail on revenue from collaborations, research and development and general and administrative costs, net loss, cash and cash equivalents, deferred income, and other balance sheet items. They also describe ProQR’s strategic collaboration with Eli Lilly, including milestone income and the framework for potential additional targets. Clinical and pipeline-related disclosures in the filings outline the status of programs such as AX-0810, AX-2402, AX-2911, and AX-1412, along with planned milestones and study objectives.
On Stock Titan, ProQR filings are updated in step with EDGAR so users can review new 6-K submissions and other forms as they appear. AI-powered summaries help explain the key points of lengthy documents, highlight important changes in financials, and clarify technical language around RNA editing, clinical trial design, and collaboration terms. Users can quickly navigate to quarterly reports, annual Form 20-F information, and current reports that capture major business and clinical events, supporting deeper due diligence on PRQR’s regulatory and financial disclosures.
ProQR Therapeutics N.V. director Valerio Domenico filed an initial ownership report showing his equity position in the company. He directly holds 420,729 Ordinary Shares and has additional indirect exposure through a Valerio family foundation, for which he disclaims beneficial ownership except for any pecuniary interest.
He also holds multiple employee share options over Ordinary Shares with exercise prices ranging from $1.98 to $15.78 per share and expiration dates between 2026 and 2035. These options give him rights to buy additional shares over time as they vest, aligning part of his compensation with ProQR’s long-term share performance.
ProQR Therapeutics N.V. director and Chief Scientific Officer Gerardus Johannes Platenburg has filed an initial statement of beneficial ownership. The filing lists direct holdings of 824,388 Ordinary Shares.
It also details multiple option grants to buy Ordinary Shares at exercise prices ranging from
The transaction summary shows holding entries only, with no reported purchases, sales, exercises, gifts, or tax-withholding dispositions in this filing.
ProQR Therapeutics N.V. director Martin Alexander Maier reported his holdings of share options that give him the right to buy Ordinary Shares at fixed prices. The filing lists several option grants with exercise prices between
The derivative positions include options over 500 Ordinary Shares at an exercise price of
ProQR Therapeutics N.V. director Alison Frances Lawton filed an initial ownership report listing multiple share option awards over Ordinary Shares. These options have exercise prices ranging from 1.9800 to 15.7800 and expiration dates between 2026 and 2035, all held directly.
Footnotes explain that some options are fully vested, while others vest over time. For several grants, 25% of the shares vest on January 1 of 2024, 2025, 2026, or 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to her continuous service to the company.
ProQR Therapeutics N.V. Chief Financial Officer Dennis Hom filed an initial ownership report showing holdings of share options over Ordinary Shares. He reports options covering 750,000 shares at an exercise price of $1.66 expiring on April 30, 2035 and options over 250,000 shares at $2.02 expiring on December 31, 2035, with vesting beginning in 2026 and 2027 and continuing in quarterly installments, subject to his continued service.
ProQR Therapeutics N.V. director Theresa Heggie filed an initial ownership report showing option-based and share holdings in the company. She directly holds several "Share Option (Right to Buy)" awards on Ordinary Shares, including 100,000 underlying shares at an exercise price of
ProQR Therapeutics N.V. director Bart Filius filed an initial ownership report detailing his stock option holdings. The Form 3 lists multiple options to purchase ordinary shares at fixed exercise prices, with expiration dates ranging from 2029 through 2035.
One option grant is noted as fully vested, while others vest 25% on specific January 1 dates from 2024 through 2027, with the remaining 75% vesting in 12 equal quarterly installments, subject to his continued service. The filing reports holdings only and does not show any recent share purchases or sales.
ProQR Therapeutics N.V. Chief Executive Officer Daniel Anton de Boer has filed an initial ownership report listing a series of share options over Ordinary Shares. These options carry exercise prices between $0.66 and $15.78 per share, with expirations from 2026 through 2035. The filing shows existing option holdings only, with no open-market purchases or sales reported.
ProQR Therapeutics N.V. director Begona Carreno-Gomez has reported existing holdings of five share option awards over Ordinary Shares. These options carry exercise prices of
ProQR Therapeutics N.V. director Shannon James Samuel filed an initial Form 3 reporting his equity holdings in the company. The filing lists multiple employee share options over ordinary shares with exercise prices ranging from
The Form 3 shows direct ownership of 61,538 ordinary shares of ProQR Therapeutics and a series of vested and time-vested options that continue to vest in quarterly installments, subject to his continuous service with the company.